Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Pediatría | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Completado
Fase 3
ClinicalTrials.gov
Effect of Duloxetine 30/60 mg Once Daily Versus Placebo in Adolescents With Juvenile Primary Fibromyalgia Syndrome
INTERVENTIONAL
Inicio: 1 de mar de 2011
ID: NCT01237587
Completado
Fase 3
ClinicalTrials.gov
Clinical Outcome of Newborn Infants With Suspected Nosocomial Coagulase-negative Staphylococcal Sepsis Treated With Cefazolin or Vancomycin. A Non-inferiority, Randomized, Controlled Trial
INTERVENTIONAL
Inicio: 1 de mar de 2007
ID: NCT01867138
Completado
ClinicalTrials.gov
Population Pharmacokinetics Study of Benznidazole in Children With Chagas Disease
INTERVENTIONAL
Inicio: 1 de abr de 2007
ID: NCT00699387
Completado
ClinicalTrials.gov
Post Authorization Study to Monitor Efficacy, Effectiveness and Safety of Teduglutide (Revestive®) in Adult and Pediatric Patients With Short Bowel Syndrome in Argentina
OBSERVATIONAL
Inicio: 5 de nov de 2020
ID: NCT04877431
Completado
Fase 3
ClinicalTrials.gov
EFFICACY, SAFETY AND TOLERABILITY OF TOFACITINIB FOR TREATMENT OF POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS (JIA) IN CHILDREN AND ADOLESCENT SUBJECTS
INTERVENTIONAL
Inicio: 10 de jun de 2016
ID: NCT02592434
Desconocido
Fase 2
ClinicalTrials.gov
An Open-Label Study of a Once Daily Dose of Emtricitabine in Combination With Other Antiretroviral Agents in HIV-Infected Pediatric Patients
INTERVENTIONAL
ID: NCT00017992
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric Participants
INTERVENTIONAL
Inicio: 16 de ene de 2014
ID: NCT02016924
Reclutando
Fase 3
ClinicalTrials.gov
A Phase III, Multicenter, Open-Label, Uncontrolled Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
INTERVENTIONAL
Inicio: 31 de mar de 2026
ID: NCT05199688
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-blind, Placebo-controlled, Cross-over Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Attacks in Adolescents and Adults With Hereditary Angioedema
INTERVENTIONAL
Inicio: 26 de feb de 2024
ID: NCT06343779
Completado
Fase 4
ClinicalTrials.gov
An Open-Label, Non-Comparative Study to Assess the Pharmacokinetics, Safety and Efficacy of Topical Retapamulin (SB-275833) Ointment, 1%, Twice Daily for Five Days in the Treatment of Uncomplicated Skin and Skin Structure Infections in Pediatric Subjects Aged 2 to 24 Months
INTERVENTIONAL
Inicio: 1 de sept de 2007
ID: NCT00555061
Reclutando
Fase 3
ClinicalTrials.gov
18-month Double-blind, Randomized, Placebo-controlled, Multicenter, Phase 3 Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease and in Late-infantile and Juvenile-onset Forms of GM1 Gangliosidosis or GM2 Gangliosidosis
INTERVENTIONAL
Inicio: 30 de jun de 2025
ID: NCT07054515
Terminado
Fase 2
ClinicalTrials.gov
Open-label, Single-arm Trial to Evaluate Antitumor Activity, Safety, and Pharmacokinetics of Isatuximab Used in Combination With Chemotherapy in Pediatric Patients From 28 Days to Less Than 18 Years of Age With Relapsed/Refractory B or T Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia in First or Second Relapse
INTERVENTIONAL
Inicio: 6 de ago de 2019
ID: NCT03860844
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-blinded, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of ALXN1850 (Recombinant Alkaline Phosphatase) Administered Subcutaneously in Adolescent (12 to < 18 Years of Age) and Adult Participants With Hypophosphatasia Who Have Not Previously Been Treated With Asfotase Alfa
INTERVENTIONAL
Inicio: 3 de ene de 2024
ID: NCT06079281
Completado
Fase 2
ClinicalTrials.gov
An Open-label, Sequential, Ascending, Repeated Dose-finding Study of Sarilumab, Administered With Subcutaneous (SC) Injection, in Children and Adolescents, Aged 2 to 17 Years, With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA) Followed by an Extension Phase
INTERVENTIONAL
Inicio: 6 de sept de 2016
ID: NCT02776735
Activo, no recluta
Fase 3
ClinicalTrials.gov
A 2-year Randomized, 3-arm, Double-blind, Non-inferiority Study Comparing the Efficacy and Safety of Ofatumumab and Siponimod Versus Fingolimod in Pediatric Patients With Multiple Sclerosis Followed by an Open-label Extension
INTERVENTIONAL
Inicio: 5 de oct de 2021
ID: NCT04926818
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter Variable Length Study to Assess the Efficacy and Safety of PT010 Relative to PT009 and Symbicort® in Adult and Adolescent Participants With Inadequately Controlled Asthma
INTERVENTIONAL
Inicio: 15 de dic de 2020
ID: NCT04609878
Reclutando
ClinicalTrials.gov
Oncological Treatment During Pregnancy: Pharmacokinetics of Chemotherapy and Long Term Follow up of the Offspring
OBSERVATIONAL
Inicio: 1 de ago de 2005
ID: NCT00330447
Reclutando
Fase 2
ClinicalTrials.gov
An Open-label, Sequential, Ascending, Repeated Dose-finding Study of Sarilumab, Administered With Subcutaneous (SC) Injection, in Children and Adolescents, Aged 1 to 17 Years, With Systemic Juvenile Idiopathic Arthritis (sJIA), Followed by an Extension Phase
INTERVENTIONAL
Inicio: 9 de ago de 2018
ID: NCT02991469
Completado
Fase 2
ClinicalTrials.gov
An Open-label, Long Term Extension Study for Treatment of Pulmonary Arterial Hypertension in Paediatric Patients Aged 8 Years up to 18 Years Who Have Participated in AMB112529 and in Whom Continued Treatment With Ambrisentan is Desired
INTERVENTIONAL
Inicio: 21 de jun de 2011
ID: NCT01342952
Completado
Fase 2
ClinicalTrials.gov
A Phase 2, Randomized, Placebo-controlled, Single-blind Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered In Either 2- Or 3-dose Regimens In Healthy Subjects Aged Greater Than Or Equal To 11 To <19 Years
INTERVENTIONAL
Inicio: 3 de mar de 2011
ID: NCT01299480
Anterior
1
...
20
21
22
...
434
Siguiente
Filtros